相关实验视频

Updated: Jan 9, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

循环的结构导向设计:一种强大的抑制剂,向PD-1/PD-L1轴,具有抗瘤活性

Wenyu Peng^1,2, Wenyu Gu^1,2, Wujuan Chen^1,2

¹Key Laboratory of Tropical Resources, School of Pharmaceutical Sciences, Hainan University, The Ministry of Education of the People's Republic of China, Haikou 570228, China.

International journal of molecular sciences

|December 11, 2025

概括

一种新型循环抑制剂PD-1-0520有效地阻断PD-1/PD-L1相互作用,增强抗瘤免疫力. 这种具有强大的抗瘤活性,并改善T细胞功能,为癌症免疫治疗提供了一个有前途的新策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物化学生物化学

背景情况:

编程细胞死亡蛋白1 (PD-1) 和其连接体PD-L1通路是癌症免疫疗法的关键标.
目前的单克隆抗体疗法面临诸多挑战,包括高成本和有限的瘤透率.

研究的目的:

开发一种针对PD-1/PD-L1相互作用的新型循环抑制剂.
在临床前癌症模型中评估抑制剂PD-1-0520的疗效和安全性.

主要方法:

基于PD-L1片段的循环的基于结构的设计.
分子动力学查,体外检测和体内研究,对携带瘤的小鼠进行.
对瘤抑制,免疫细胞透和激活标记物的评估.

主要成果:

PD-1-0520证明了对PD-1/PD-L1相互作用的强烈抑制.
该在B16-F10模型中实现了68%的瘤抑制率,没有系统毒性.
PD-1-0520促进了CD8+T细胞的透和激活,重塑了瘤的免疫微环境.

结论:

PD-1-0520是一种有前途的循环抑制剂,用于癌症免疫治疗.
基于结构的设计策略为开发蛋白质-蛋白质相互作用抑制剂提供了一种新的方法.

关键词:

在PD-1中使用PD-1.在PD-L1中.癌症免疫疗法免疫疗法这是一种循环类.免疫检查点封锁封锁蛋白质蛋白质相互作用

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...